You are here:Home-Chemical Inhibitors & Agonists-PI3K/Akt/mTOR Pathway-PI3K-GDC-0980
GDC-0980

Chemical Structure : GDC-0980

CAS No.: 1032754-93-0

GDC-0980 (Apitolisib;GNE 390;GDC0980;RG 7422)

Catalog No.: PC-43426Not For Human Use, Lab Use Only.

GDC-0980 (Apitolisib, GNE 390, RG 7422) is a potent, selective, orally available class I PI3K/mTOR inhibitor with IC50 of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, inhibits mTOR inhibitor with Ki of 17 nM.

Packing Price Stock Quantity
10 mg $128 In stock
25 mg $218 In stock
50 mg $358 In stock
100 mg $558 In stock
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

GDC-0980 (Apitolisib, GNE 390, RG 7422) is a potent, selective, orally available class I PI3K/mTOR inhibitor with IC50 of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, inhibits mTOR inhibitor with Ki of 17 nM.
GDC-0980 displays remarkably selectivity for several other members of the closely related PIKK family kinases, including C2alpha, C2beta, VPS34 I, PI4Kalpha, PI4Kbeta and DNA-PK.
GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, reduces viability in multiple cancer cell lines by cell-cycle inhibition and induction of apoptosis (prostate IC50<200 nM, NSCLC lines <200 nM).
GDC-0980 potently inhibits tumor growth in xenograft models with activated PI3K, loss of LKB1 or PTEN.

Physicochemical Properties

M.Wt 498.6011
Formula C23H30N8O3S
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

1-Propanone, 1-[4-[[2-(2-amino-5-pyrimidinyl)-7-methyl-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]-1-piperazinyl]-2-hydroxy-, (2S)-

References

1. Wallin JJ, et al. Mol Cancer Ther. 2011 Dec;10(12):2426-36.

2. Sutherlin DP, et al. J Med Chem. 2011 Nov 10;54(21):7579-87.

3. Spoerke JM, et al. Clin Cancer Res. 2012 Dec 15;18(24):6771-83.et al.

4. Makhov PB, et al. Mol Cancer Ther. 2012 Jul;11(7):1510-7.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: